Greenland Mines (GRML) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OKYO Pharma (OKYO) has outperformed Greenland Mines (GRML) over the past year, losing 30.5% versus a loss of 80.4%. Greenland Mines is the larger company by market cap ($77.8 million vs $74.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRML | OKYO |
|---|---|---|
| Share price | $5.83 | $1.41 |
| Market cap | $77.81M | $74.00M |
| 1-day change | -8.62% | -3.42% |
| YTD return | -59.65% | -31.88% |
| 1-year return | -80.37% | -30.54% |
| EPS (TTM) | $-8.87 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.00 | $3.20 |
| 52-week low | $2.82 | $1.27 |
| Distance from 52-week high | -84.24% | -55.94% |
| Average volume | 7.99M | 104.86K |
| Shares outstanding | 13.35M | 52.48M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKYO has outperformed GRML by 49.8 percentage points over the past year.
GRML vs OKYO FAQ
Which is bigger, Greenland Mines or OKYO Pharma?
Greenland Mines (GRML) is larger, with a market capitalization of $77.81M compared with $74.00M for OKYO Pharma (OKYO).
Which stock has performed better over the past year, GRML or OKYO?
OKYO returned -30.54% over the past 12 months, compared with -80.37% for GRML (price return, excluding dividends). Past performance does not predict future results.
Are Greenland Mines and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.